AAIPharma and CML Announce the Appointments of Vice Presidents
News Oct 10, 2014
AAIPharma Services Corp. and Cambridge Major Laboratories, Inc. have announced the appointments of Ted Dolan as Vice President, API Operations and Syed T. Husain as Vice President, API Business Unit.
“Mr. Dolan’s experience operating and managing teams in the chemical and pharmaceutical industries will further solidify our leadership in API manufacturing - this is an exciting time for our organization,” said Stephan Kutzer, Ph.D., Chief Executive Officer.
Mr. Dolan recently served as the Vice-President of Global Operations at Johnson Matthey. He has thirty years of operations and management experience in the refining, automotive, fine chemical, and pharmaceutical (API) industries. He has a B.S. degree in Chemical Engineering from the University of Notre Dame and an M.B.A. in Finance and Production Management from St. Joseph’s University.
Mr. Dolan said, “I am excited to join a dynamic team as we provide leading capabilities in API manufacturing.”
Addressing Mr. Husain’s appointment, Dr. Kutzer added, “Mr. Husain’s diverse experience in both Business Development and Operations will allow us to continue to provide our customers with best-in-class solutions in the API manufacturing industry.”
Mr. Husain recently served as the Head of Business Development and Business Team at Lonza. He has over 10 years of in-depth experience in sales, business development, marketing and operations. He has a B.S. degree in Chemical Engineering from the New Jersey Institute of Technology and an M.B.A. from Cornell University.
Mr. Husain said, “I am delighted to join the team, and I look forward to helping us provide the best services in the industry.”
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE